Christophe Weber wins shareholder approval as chief operating officer at Takeda as expected, setting up a leadership change at Japan’s top, and oldest, drug company over the opposition of some family members.
SINGAPORE - Shareholders of Takeda Pharmaceutical Co. Ltd. approved the appointment Christophe Weber as chief operating officer, the company said June 27, placing him one step closer to the top job of CEO held by Yasuchika Hasegawa who is leading a drive to change the company to an outward focus.
Weber joined Takeda in April as chief operating officer and should succeed Hasegawa next year, making him one of less...
Country recommends eights new drugs for approval, including six for rare diseases, and also announces macroeconomic policy the pharma industry says would enable some reimbursement prices to be raised.
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
Australia is reviewing its human tissue laws for the first time in almost 50 years, and is hoping to reduce barriers to access for scientific researchers, for instance by addressing issues with access to cell lines for developing drugs.
